[
  {
    "ts": null,
    "headline": "Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade",
    "summary": "Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade",
    "url": "https://finnhub.io/api/news?id=9cdfa2dfbf0baebead37b72699c6f1fc1c9670c0fc85c53f93b32e47a1856261",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739294443,
      "headline": "Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade",
      "id": 132676477,
      "image": "",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=9cdfa2dfbf0baebead37b72699c6f1fc1c9670c0fc85c53f93b32e47a1856261"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corp. stock underperforms Tuesday when compared to competitors",
    "summary": "Incyte Corp. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d930469423418a307d619c90102be42c429ac810234c772735a07ddbc0b7a963",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739294280,
      "headline": "Incyte Corp. stock underperforms Tuesday when compared to competitors",
      "id": 132698116,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d930469423418a307d619c90102be42c429ac810234c772735a07ddbc0b7a963"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags",
    "summary": "Incyte ( NASDAQ:INCY ) Full Year 2024 Results Key Financial Results Revenue: US$4.24b (up 15% from FY 2023). Net...",
    "url": "https://finnhub.io/api/news?id=697b9042e179426dd6be2f62a96557a1edeb4c9bb285f747e84e8a4e7b65ef18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739268380,
      "headline": "Incyte Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags",
      "id": 133193458,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte ( NASDAQ:INCY ) Full Year 2024 Results Key Financial Results Revenue: US$4.24b (up 15% from FY 2023). Net...",
      "url": "https://finnhub.io/api/news?id=697b9042e179426dd6be2f62a96557a1edeb4c9bb285f747e84e8a4e7b65ef18"
    }
  },
  {
    "ts": null,
    "headline": "Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025",
    "summary": "Financial analysis of Incyte's Q4 earnings, future growth potential, and stock rating with a 34% upside potential to $94/share.",
    "url": "https://finnhub.io/api/news?id=037718abfef1e5eb4cf93bec711d46172ea23241a600d68bafbd4de747f2a1b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739259000,
      "headline": "Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025",
      "id": 132657504,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1893449171/image_1893449171.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Financial analysis of Incyte's Q4 earnings, future growth potential, and stock rating with a 34% upside potential to $94/share.",
      "url": "https://finnhub.io/api/news?id=037718abfef1e5eb4cf93bec711d46172ea23241a600d68bafbd4de747f2a1b2"
    }
  },
  {
    "ts": null,
    "headline": "Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule",
    "summary": "Aclaris stock plummets 70% since Sep 2023. Promising ATI-045 results spark debate; past failures fuel skepticism.",
    "url": "https://finnhub.io/api/news?id=02e01fac1aeb6a9f9799855f17e8617b438dd8b0cdd4df9cd2289c11ecf5cec9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739257758,
      "headline": "Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule",
      "id": 132657438,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1972341389/image_1972341389.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Aclaris stock plummets 70% since Sep 2023. Promising ATI-045 results spark debate; past failures fuel skepticism.",
      "url": "https://finnhub.io/api/news?id=02e01fac1aeb6a9f9799855f17e8617b438dd8b0cdd4df9cd2289c11ecf5cec9"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook",
    "summary": "Incyte Corp (INCY) reports a 15% revenue increase for 2024, driven by robust sales of Jakafi and Opzelura, while maintaining a solid cash position and outlining ambitious 2025 guidance.",
    "url": "https://finnhub.io/api/news?id=878fce0a887c1cf5516de6588a82fec60c8d03976fd468f4622bef2061cf0a0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739257456,
      "headline": "Incyte Corp (INCY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook",
      "id": 133193459,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corp (INCY) reports a 15% revenue increase for 2024, driven by robust sales of Jakafi and Opzelura, while maintaining a solid cash position and outlining ambitious 2025 guidance.",
      "url": "https://finnhub.io/api/news?id=878fce0a887c1cf5516de6588a82fec60c8d03976fd468f4622bef2061cf0a0b"
    }
  },
  {
    "ts": null,
    "headline": "Q4 2024 Incyte Corp Earnings Call",
    "summary": "Q4 2024 Incyte Corp Earnings Call",
    "url": "https://finnhub.io/api/news?id=b79915923e2f5d441f3ae6d6c8aebb37ab66e6b05e64d813ae9e2092c6912c5d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739248092,
      "headline": "Q4 2024 Incyte Corp Earnings Call",
      "id": 133193460,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Q4 2024 Incyte Corp Earnings Call",
      "url": "https://finnhub.io/api/news?id=b79915923e2f5d441f3ae6d6c8aebb37ab66e6b05e64d813ae9e2092c6912c5d"
    }
  }
]